In the BioHarmony Drug Report Database

"Preview" Icon

Mogamulizumab-kpkc

Poteligeo (mogamulizumab) is an antibody pharmaceutical. Mogamulizumab was first approved as Poteligeo on 2018-08-08. It is used to treat mycosis fungoides and sezary syndrome in the USA. It has been approved in Europe to treat mycosis fungoides and sezary syndrome. The pharmaceutical is active against C-C chemokine receptor type 4.

 

Trade Name

 

Poteligeo
 

Common Name

 

mogamulizumab
 

ChEMBL ID

 

CHEMBL1743041
 

Indication

 

mycosis fungoides, sezary syndrome
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Mogamulizumab-kpkc structure rendering